Core Viewpoint - The company has received approval for clinical trials of KYS2301, a novel drug targeting atopic dermatitis, which presents significant market potential as it is the first CCR8-targeting peptide inhibitor globally [1] Company Summary - The company announced the receipt of a clinical trial approval notice from the National Medical Products Administration for KYS2301, a first-class chemical new drug [1] - KYS2301 is a specific inhibitor of chemokine receptor 8 (CCR8) and is intended for the treatment of atopic dermatitis [1] - The total research and development investment for KYS2301 has reached approximately 44.93 million yuan [1] Industry Summary - Atopic dermatitis is a common chronic relapsing inflammatory skin disease, with the global patient population reaching 649 million in 2019 and expected to grow to 755 million by 2030 [1] - Currently, there are no marketed peptide drugs targeting the CCR8 receptor, indicating a strong market opportunity for KYS2301 [1] - The company is required to complete Phase I-III clinical trials and compile submission materials for product registration following the receipt of the clinical trial notice [1]